

# Fatigue in chronic liver disease: risk factors and treatment options

<b>Submission date</b> 04/11/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 05/11/2021	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 02/09/2025	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Primary biliary cholangitis (PBC) is a type of liver disease that can get gradually worse over time. Fatigue is a common symptom and the major 'unmet need' in the management of patients with PBC. There are few prospective studies addressing the development of PBC-associated fatigue over time and the mechanisms underlying its development and maintenance are poorly understood. The aim of this study is to identify risk factors that determine the course and severity of fatigue in PBC.

### Who can participate?

Adults from the age of 18 with a diagnosis of PBC or primary sclerosing cholangitis (PSC), a rare disease that attacks the bile ducts.

### What does the study involve?

The associations and interactions between risk factors and fatigue will be assessed and compared in patients with PBC (a patient group severely affected by fatigue) and n= 240 patients with PSC (a group much less affected by fatigue). These variables will be monitored to identify factors that determine the severity and persistence of fatigue over time. An experimental study and interviews will be carried out in a sample of patients with newly diagnosed PBC. Their fecal microbiome (micro-organisms) will be analysed in order to find alterations in patients with high and low fatigue severity.

### What are the possible benefits and risks of participating?

The study will investigate the natural course of fatigue in PBC (and PSC), and the study procedure will not influence patients' regular medical treatment. Both patient groups receive 'care as usual' and there are no disadvantages for participants compared to non-participants. However, results will enhance the understanding of the causes of PBC fatigue and increase the knowledge on the predictive role of risk factors that are amenable to change. The study results will form a basis for future treatment and intervention approaches that aim to improve patients' quality of life.

### Where is the study run from?

The study is being conducted by the YAEL - Center for Autoimmune Liver Diseases and the

Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Hamburg-Eppendorf, Germany. Microbiome analyses will be conducted in collaboration with the Institute of Clinical Molecular Biology (IKMB) of Kiel University (Germany).

When is the study starting and how long is it expected to run for?  
May 2020 to September 2025

Who is funding the study?  
Deutsche Forschungsgemeinschaft, DFG (German Research Foundation) (Germany)

Who is the main contact?  
Prof. Dr med. Christoph Schramm, c.schramm@uke.de  
Dr. phil. Anne Toussaint, a.toussaint@uke.de

### **Study website**

<https://www.uke.de/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/index.html>

## **Contact information**

**Type(s)**  
Scientific

**Contact name**  
Dr Anne Toussaint

**Contact details**  
Martinistraße 52  
Hamburg  
Germany  
20246  
+49 (0) 40 7410 - 52972  
a.toussaint@uke.de

**Type(s)**  
Scientific

**Contact name**  
Prof Christoph Schramm

**Contact details**  
Martinistraße 52  
Hamburg  
Germany  
20246  
+49 (0) 40 7410 - 52545  
c.schramm@uke.de

## **Additional identifiers**

**EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

DFG grant numbers TO 908/3-1 and SCHR 781/7-1

## **Study information**

**Scientific Title**

Fatigue in primary biliary cholangitis: factors associated with severity and persistence as future therapeutic targets

**Acronym**

SOMA.LIV

**Study objectives**

Hypotheses 1: Biomedical and psychosocial factors account for differences in fatigue experience between patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis.

Hypothesis 2: Biomedical risk factors (e.g. inflammatory cytokines, autonomic dysfunction) and psychological risk factors (e.g. depression, avoidance) predict the severity of fatigue among patients with PBC at 12-month follow-up, and their interplay determines its course over time.

Hypothesis 3a: Intestinal microbiota alterations are independently or conjointly with other biomedical and psychosocial factors associated with the severity of fatigue in patients with PBC.

Hypothesis 3b: Expectation of fatigue severity independently or conjointly with biomedical and psychosocial factors determines the severity of fatigue in patients with PBC.

Hypothesis 4: Higher anticipated fatigue prior to a stair-climbing task will correlate with worse performance and more severe post fatigue.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 25/01/2021, Ethics Committee of the Hamburg Medical Association (Ethik-Kommission der Ärztekammer Hamburg, Weidestraße 122 b, 22083, Hamburg, Germany; +49 (0) 40 202299-240; [ethik@aekhh.de](mailto:ethik@aekhh.de)), ref: 2020-10196-BO-ff

**Study design**

Non-interventional prospective cohort study; mixed-methods design

**Primary study design**

Observational

**Secondary study design**

Cohort study

**Study setting(s)**

Hospital

**Study type(s)**

Other

**Participant information sheet**

See study outputs table

**Health condition(s) or problem(s) studied**

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)

**Interventions**

A prospective cohort study will be conducted in order to compare fatigue experience and related factors in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Using a mixed-methods approach, the role of symptom perception and expectations in the development and maintenance of fatigue will be further examined in a subgroup of newly diagnosed patients with PBC.

**Prospective cohort study:**

In the prospective cohort study, the natural course of fatigue in patients with PBC compared to PSC (a control cholestatic liver disease group much less affected by fatigue) will be investigated. Follow-up measurements will take place after 6 and 12 months. Patient data will be collected through self-report questionnaires, semi-structured interviews, and blood and stool samples.

**Experimental study:**

In an experimental study, a subgroup of newly diagnosed patients with PBC will rate their momentary fatigue and anticipated fatigue prior to a self-paced stair-climbing task. After the task, they will re-rate experienced fatigue.

**Qualitative study:**

Qualitative interviews will be conducted in the subsample of newly diagnosed patients in order to complement the quantitative data. Patients will undergo semi-structured interviews before their first medical consultation at the YAEL - Center, and at 6- and 12-month follow-up. Interview questions will assess patients' symptom perception, management strategies, causal attributions and expectations on fatigue.

**Microbiome analysis:**

Shotgun metagenomic sequencing will be performed in order to identify bacterial species and functional annotations in patients with PBC and PSC, and high versus low fatigue scores, respectively.

**Intervention Type**

Other

**Primary outcome measure**

The severity of fatigue assessed using the Fatigue Visual Analogue Scale (Fatigue-VAS) score and the Primary Biliary Cirrhosis-40 (PBC-40) fatigue domain score at baseline, after 6 months, and after 12 months

**Secondary outcome measures**

1. Total somatic symptom severity measured using the Patient Health Questionnaire-15 (PHQ-15) at baseline, 6 months, and 12 months
2. Symptom intensity measured using a Numeric Rating Scale (NRS) at baseline, 6 months, and 12 months
3. Pruritus severity measured using a Numeric Rating Scale (NRS) at baseline, 6 months, and 12 months
4. Symptom interference with daily activities using a Numeric Rating Scale (NRS) at baseline, 6 months, and 12 months
5. Symptom-related disability measured using the Pain Disability Index (PDI) at baseline, 6 months, and 12 months
6. General mental and physical quality of life measured using the Short-Form Health Survey (SF-12) at baseline, 6 months, and 12 months
7. Disability-specific quality of life measured using the respective subdomain of the Primary Biliary Cirrhosis-40 (PBC-40) at baseline, 6 months, and 12 months

**Overall study start date**

01/05/2020

**Completion date**

30/09/2025

## Eligibility

**Key inclusion criteria**

1. Clinical diagnosis of PBC (PSC)
2. Sufficient oral and written German language proficiency
3. Provision of written consent

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

480

**Total final enrolment**

480

**Key exclusion criteria**

1. Advanced cirrhosis (Child Pugh score  $\geq 8$ )
2. Decompensated liver disease (autoimmune hepatitis or chronic viral hepatitis B or C)
3. Clinically significant untreated intercurrent medical condition associated with fatigue (i.e. hypothyroidism, anaemia, fibromyalgia, rheumatoid arthritis, systemic lupus erythematosus and manifest depression)
4. Antibiotic treatment during the past 6 weeks (exclusion only in microbiome study)

5. Ongoing participation in clinical trials on fatigue
6. Intercurrent active or latent infection
7. Florid psychosis
8. Substance abuse disorder
9. Acute suicidality

**Date of first enrolment**

21/03/2022

**Date of final enrolment**

31/12/2023

## **Locations**

**Countries of recruitment**

Germany

**Study participating centre**

**University Medical Centre Hamburg-Eppendorf**

YEAL-Center for Autoimmune Liver Diseases

Martinistraße 52

Hamburg

Germany

20246

**Study participating centre**

**University Medical Centre Hamburg-Eppendorf**

Department of Psychosomatic Medicine and Psychotherapy

Martinistraße 52

Hamburg

Germany

20246

**Study participating centre**

**Christian-Albrechts-University Kiel**

Institute of Clinical Molecular Biology

Rosalind-Franklin-Straße 12

Kiel

Germany

24105

## **Sponsor information**

**Organisation**

University Medical Center Hamburg-Eppendorf

**Sponsor details**

Martinistraße 52

Hamburg

Germany

20246

+49 (0)40 74101

info@uke.de

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.uke.de/>

**ROR**

<https://ror.org/01zgy1s35>

**Funder(s)****Funder type**

Charity

**Funder Name**

Deutsche Forschungsgemeinschaft

**Alternative Name(s)**

German Research Association, German Research Foundation, DFG

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Germany

**Results and Publications**

Publication and dissemination plan

The study protocol will be submitted for publication. According to the WHO Statement on Public Disclosure of Clinical Trials (<https://www.who.int/ictrp/results/reporting/en/>), the main findings will be submitted for publication in a high-impact peer-reviewed journal within 12 months of study completion.

### **Intention to publish date**

31/03/2026

### **Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in a publically available repository (e.g., DRYAD Digital Repository; <https://datadryad.org/stash>). The study protocol and statistical analysis plan will be available at the ISRCTN registry. Individual participant data that underlie the reported results in a published article will be shared after de-identification beginning 3 months and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals should be directed to Dr Anne Toussaint ([a.toussaint@uke.de](mailto:a.toussaint@uke.de)). To gain access, data requestors will need to sign a data access agreement. Informed consent from participants was obtained.

### **IPD sharing plan summary**

Stored in publicly available repository

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	version 2	17/01/2021	05/11/2021	No	Yes
<a href="#">Protocol article</a>		07/12/2022	06/01/2023	Yes	No